| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6abba73c49e6d0bdfad5bc9352c82dd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b7d2eafd7d0fda2888eb2246e7c893c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef3ccaba147b0add9a15ef3f7e3934d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c800496f1fa87bec72adf56a0b53320 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
| filingDate |
1998-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fff7a550d0747ce620313712a52f4df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6606480e56431251bc5d89ba61f4e157
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffaea04514c44f78c7907e1849b3e28b |
| publicationDate |
1998-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9838509-A1 |
| titleOfInvention |
Drug screen targeting lipoprotein-membrane anchorage |
| abstract |
A drug screening assay for identifying compounds for their potential effects on the long chain fatty acid dependant intracellular membrane anchorage sites of lipoproteins. Membranes-anchoring-target are incubated in the presence of the compound to be tested and the proportion of the target that is released by the compound is detected and quantitated. The benchmark for this assay are the prenylated proteins such as the farnesylated and palmitoylated oncogenic ras trigger proteins which are displaced from their anchorage at the intracellular plasma membrane by derivatives of Farnesyl Thiosalicylic Acid (FTS). The assay is adaptable to flexibly assay a large variety of anchored targets using a wide range of labeling and detection techniques in test wells, tissue culture, and in animals as injected cells or transgenic, thereby directly addressing a wide range of pharmacologically relevant needs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0229031-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0229031-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6946485-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013052765-A1 |
| priorityDate |
1997-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |